A placebo-controlled trial of buspirone for the treatment of marijuana dependence

Drug and Alcohol Dependence

Volumn 105, Issue 1-2, 2009, Pages 132-138

  McRae Clark, Aimee L ^a   Carter, Rickey E ^b   Killeen, Therese K ^a   Carpenter, Matthew J ^a,b   Wahlquist, Amy E ^b   Simpson, Stacey A ^a   Brady, Kathleen T ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Buspirone; Marijuana; Motivational interviewing; Placebo

Indexed keywords

BUSPIRONE; PLACEBO;

ADULT; ALLERGY; ANXIETY; ARTICLE; CANNABIS ADDICTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIZZINESS; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FLU LIKE SYNDROME; FLUSHING; GASTROINTESTINAL DISEASE; HAMILTON ANXIETY SCALE; HUMAN; INSOMNIA; MALE; MOTIVATION; MUSCULOSKELETAL DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SELF REPORT; SEXUAL DYSFUNCTION; SIDE EFFECT; SKIN TINGLING; SWEATING; TASTE DISORDER; TRANQUILIZING ACTIVITY; TREMOR; UNPLEASANT DREAM; WITHDRAWAL SYNDROME; XEROSTOMIA;

ADULT; ANTI-ANXIETY AGENTS; ANXIETY; BUSPIRONE; CANNABINOIDS; CANNABIS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MARIJUANA ABUSE; MOTIVATION; PSYCHIATRIC STATUS RATING SCALES; QUESTIONNAIRES; SAMPLE SIZE; SUBSTANCE WITHDRAWAL SYNDROME; TREATMENT OUTCOME;

CANNABIS SATIVA;

EID: 69949096473     PISSN: 03768716     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2009.06.022     Document Type: Article

References (43)

1. Agosti V., Nunes E., and Levin F. Rates of psychiatric comorbidity among U.S. residents with lifetime cannabis dependence. Am. J. Drug Alcohol Abuse 28 (2002) 643-652
2. Budney A.J., and Hughes J.R. The cannabis withdrawal syndrome. Curr. Opin. Psychiatry 19 (2006) 233-238
3. Budney A.J., Hughes J.R., Moore B.A., and Vandrey R. Review of the validity and significance of cannabis withdrawal syndrome. Am. J. Psychiatry 161 (2004) 1967-1977
4. Budney A.J., Novy P.L., and Hughes J.R. Marijuana withdrawal among adults seeking treatment for marijuana dependence. Addiction 94 (1999) 1311-1321
5. Carroll K.M., Ball S.A., Nich C., O'Connor P.G., Eagan D., Frankforter T.L., Triffleman E.G., Shi J., and Rounsaville B.J. Targeting behavioral therapies to enhance naltrexone treatment of opioid dependence: efficacy of contingency management and significant other involvement. Arch. Gen. Psychiatry 58 (2001) 755-761
6. Carroll K.M., Kosten T.R., and Rounsaville B.J. Choosing a behavioral therapy platform for pharmacotherapy of substance users. Drug Alcohol Depend. 75 (2004) 123-134
7. Carroll K.M., Sinha R., Nich C., Babuscio T., and Rounsaville B. Contingency management to enhance naltrexone treatment of opioid dependence: a randomized clinical trial of reinforcement magnitude. Exp. Clin. Psychopharmacol. 10 (2002) 54-63
8. Conway K.P., Compton W., Stinson F.S., and Grant B.F. Lifetime comorbidity of DSM-IV mood and anxiety disorders and specific drug use disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. J. Clin. Psychiatry 67 (2006) 247-257
9. Copersino M.L., Boyd S.J., Tashkin D.P., Huestis M.A., Heishman S.J., Dermand J.C., Simmons M.S., and Gorelick D.A. Cannabis withdrawal among non-treatment-seeking adult cannabis users. Am. J. Addict. 15 (2006) 8-14
10. Darmani N.A., Janoyan J.J., Kumar N., and Crim J.L. Behaviorally active doses of the CB1 receptor antagonist SR 141716A increase brain serotonin and dopamine levels and turnover. Pharmacol. Biochem. Behav. 75 (2003) 777-787
11. Eison M.S., and Eison A.S. Buspirone as a midbrain modulator: anxiolysis unrelated to traditional benzodiazepine mechanisms. Drug Dev. Res. 4 (1984) 109-119
12. Eskridge K.D., and Guthrie S.K. Clinical issues associated with urine testing of substances of abuse. Pharmacotherapy 17 (1997) 497-519
13. First M.B., Spitzer R.L., Gibbon M., and Williams J.B.W. Structured Clinical Interview for Axis I DSM-IV Disorders-Patient Edition (SCID-I/P, vs 2.0) (1995), New York State Psychiatric Institute, Biometrics Research Department, New York
14. Glaser T., and Traber J. Buspirone: action on serotonin receptors in calf hippocampus. Eur. J. Pharmacol. 88 (1983) 137-138
15. Gruber A.J., Pope H.G., and Oliva P. Very long-term users of marijuana in the United States. Subst. Use Misuse 32 (1997) 249-264
16. Hamilton M. The assessment of anxiety states by rating. Br. J. Psychiatry 32 (1959) 50-55
17. Heishman S.J., Singleton E.G., and Ligouri A. Marijuana Craving Questionnaire: development and initial validation of a self-report instrument. Addiction 96 (2001) 1023-1034
18. Higgins S.T., Budney A.J., Bickel W.K., Foerg F.E., Donham R., and Badger G.J. Incentives improve outcome in outpatient behavioral treatment of cocaine dependence. Arch. Gen. Psychiatry 51 (1994) 568-576
19. Hill M.N., Sun J.C., Tse M.T.L., and Gorzalka B.B. Altered responsiveness of serotonin receptor subtypes following long-term cannabinoid treatment. Int. J. Neuropsychopharmacol. 9 (2006) 277-286
20. Huestis M.A., and Cone E.J. Differentiating new marijuana use from residual drug excretion in occasional marijuana users. J. Anal. Toxicol. 22 (1998) 445-454
21. Kastenholz K.V., and Crismon M.L. Buspirone, a novel nonbenzodiazepine anxiolytic. Clin. Pharm. 3 (1984) 600-607
22. Kouri E.M., and Pope H.G. Abstinence symptoms during withdrawal from chronic marijuana use. Exp. Clin. Psychopharmacol. 8 (2000) 483-492
23. Lader M. Can buspirone induce rebound, dependence, or abuse?. Br. J. Psychiatry 159 Suppl. (1991) 45-51
24. Levin F.R., McDowell D., Evans S., Nunes E., Akerele E., Donovan S., and Vosburg S.K. Pharmacotherapy for marijuana dependence: a double-blind, placebo-controlled pilot study of divalproex sodium. Am. J. Addict. 13 (2004) 21-32
25. Liang K.Y., and Zeger S.L. Longitudinal data analysis using generalized linear models. Biometrika 73 (1986) 13-22
26. McCullagh P., and Nelder J.A. Generalized Linear Models (1989), Chapman and Hall, London
27. McRae A.L., Budney A.J., and Brady K.T. Treatment of marijuana dependence: a review of the literature. J. Subst. Abuse Treat. 24 (2003) 369-376
28. McRae A.L., Brady K.T., and Carter R.E. Buspirone for treatment of marijuana dependence: a pilot study (Letter). Am. J. Addict. 15 (2006) 404
29. Miller W.R., Benefield G.S., and Tonigan J.S. Enhancing motivation for change in problem drinking: a controlled comparison of two therapist styles. J. Consult. Clin. Psychol. 61 (1993) 455-461
30. Nazaki M., Bauer U., Nickel T., Kathmann M., and Schlicker E. Inhibition of serotonin release in the mouse brain via presynaptic cannabinoid CB1 receptors. Naunyn-Schmeideberg's Arch. Pharmacol. 361 (2000) 19-24
31. Nordstrom B.R., and Levin F.R. Treatment of cannabis use disorders: a review of the literature. Am. J. Addict. 16 (2007) 331-342
32. Preston K.L., Silverman K., Umbricht A., DeJesus A., Montoya I.D., and Schuster C.R. Improvement in naltrexone treatment compliance with contingency management. Drug Alcohol Depend. 54 (1999) 127-131
33. Regier D.A., Farmer M.E., Rae D.S., Locke B.Z., Keith S.J., Judd L.L., and Goodwin F.K. Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. JAMA 264 (1990) 2511-2518
34. Robinson D.S., Rickels K., Feighner J., Fabre Jr. L.F., Gammans R.E., Shrotriya R.C., Alms D.R., Andary J.J., and Messina M.E. Clinical effects of the 5-HT1A partial agonists in depression: a composite analysis of buspirone in the treatment of depression. J. Clin. Psychopharmacol. 10 3 Suppl. (1990) 67S-76S
35. Russo E.B., Burnett A., Hall B., and Parker K.K. Agonistic properties of cannabidiol at 5-HT1a receptors. Neurochem. Res. 30 (2005) 1037-1043
36. Sobell M.B., and Sobell L.C. Behavioral Treatment of Alcohol Problems (1978), Plenum Press, New York
37. Steinberg K.L., Roffman R.A., Carroll K.M., McRee B., Babor T.F., Miller M., Kadden R., Duresky D., and Stephens R. Brief Counseling for Marijuana Dependence: A Manual for Treating Adults. DHHS Publication No. (SMA) 05-4022 (2005), Center for Substance Abuse Treatment, Substance Abuse and Mental Health Services Administration, Rockville, MD
38. Stinson F.R., Ruan W.J., Pickering R., and Grant B.F. Cannabis use disorders in the USA: prevalence, correlates and co-morbidity. Psychol. Med. 36 (2006) 1447-1460
39. Stout R.L., Wirtz P.W., Carbonari J.P., and DelBoca F.K. Ensuring balanced distribution of prognostic factors in treatment outcome research. J. Stud. Alcohol 12 (1994) 70-75
40. Substance Abuse and Mental Health Services Administration, Office of Applied Studies, 2008. Results from the 2007 National Survey on Drug Use and Health: National Findings (NSDUH Series H-34, DHHS Publication No. SMA 08-4343). Rockville, MD.
41. Tirado C.F., Goldman M., Lynch K., Kampman K.M., and Obrien C.P. Atomoxetine for treatment of marijuana dependence: a report on the efficacy and high incidence of gastrointestinal adverse events in a pilot study. Drug Alcohol Depend. 94 (2008) 254-257
42. United Nations Office on Drugs and Crime, 2008. 2008 World Drug Report. United Nations Publication Sales No. #.08.XI.1. Vienna, Austria.
43. Van Belle G. Statistical rules of thumb (2002), Wiley Interscience, New York